Literature DB >> 11822644

Effects of a fundholding discontinuation. An Israeli health maintenance organization natural experiment.

A Elhayany1, S Regev, M Sherf, H Reuveni, P Shvartzman.   

Abstract

OBJECTIVE: To evaluate the effects of fundholding on cost containment and after termination of the project. DESIGN AND
SETTING: Primary care practices participating in the project were allocated an itemized budget. Practices assumed authority for hospitalization, drugs, ambulatory medical diagnostic, consultant services and acquisition of minor equipment. Financial incentives were offered, but no penalties were imposed on practices where expenditure exceeded budget.
SUBJECTS: Nine primary care practices in southern Israel. MAIN OUTCOME MEASURE: Total expenditure and a breakdown of expenditure per capita.
RESULTS: Fundholding practice expenditure was compared with expenditure in the district as a whole. During the study period, total expenditure in fundholding practices rose by 12%, whereas that of the district rose by 37%. With discontinuation of the project, expenditure of the designated practices returned to the original levels, equivalent to those of the district.
CONCLUSION: Fundholding is an efficient method of cost-containment. The effect will be long lasting only if motivation is maintained.

Mesh:

Year:  2001        PMID: 11822644     DOI: 10.1080/02813430152706729

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  2 in total

Review 1.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04

2.  Association between the 2012 Health and Social Care Act and specialist visits and hospitalisations in England: A controlled interrupted time series analysis.

Authors:  James A Lopez Bernal; Christine Y Lu; Antonio Gasparrini; Steven Cummins; J Frank Wharam; Steven B Soumerai
Journal:  PLoS Med       Date:  2017-11-14       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.